Volume and share price apprecitaion seems to be related to these new guys the Co. has brought on deck. Does anybody know anything about them? Someone seems to like them anyway...
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress